Table 2.
The association between USP22 expression and clinicopathological factors in GC.
| Factor | Number of studies | Number of patients | Pooled OR (95% CI) | P value | Heterogeneity |
||
|---|---|---|---|---|---|---|---|
| I2 (%) | P value | Model | |||||
| Gender (male vs. female) | 1,2,3,4,5,6 | 802 | 1.202 (0.877–1.648) | 0.253 | 24.8 | 0.248 | Fixed |
| Age (≥60 vs. <60) | 1,2,3,4,5,6 | 802 | 1.090 (0.811–1.466) | 0.568 | 0.00 | 0.433 | Fixed |
| Tumor size (≥5 vs. <5 cm) | 1,2,5,6 | 618 | 0.693 (0.348–1.380) | 0.297 | 69.1 | 0.021 | Random |
| Tumor differentiation (well vs. poor) | 1,2,4,5,6 | 718 | 1.830 (0.948–3.531) | 0.072 | 71.6 | 0.007 | Random |
| Depth of invasion (T3-4 vs. T1-2) | 1,2,3,4,5,6 | 802 | 2.320 (0.684–7.871) | 0.177 | 90.0 | 0.000 | Random |
| Lymph node (yes vs. no) | 1,2,3,4,5,6 | 802 | 2.415 (1.082–5.389) | 0.031 | 79.1 | 0.000 | Random |
| Distant metastasis (yes vs. no) | 1,2,3,4,5,6 | 802 | 3.956 (1.365–11.464) | 0.011 | 57.6 | 0.038 | Random |
| TNM stage (III-IV vs. I-II) | 1,2,3,4,5,6 | 802 | 2.973 (1.153–7.666) | 0.024 | 88.0 | 0.000 | Random |